GENOMIC HEALTH, INC. REDWOOD CITY, Calif., Feb. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2015.
Revenue was $74.5 million in the fourth quarter of 2015, compared with $69.1 million in the fourth quarter of 2014, an increase of 8 percent. On a constant currency basis, revenue increased 9 percent compared with the same period in the prior year.
U.S. revenue was $63.9 million in the fourth quarter of 2015, an increase of 9 percent compared with the same period in the prior year. International revenue was $10.6 million in the fourth quarter of 2015, compared with $10.3 million a year ago. International revenue was reduced by $0.6 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.
Revenue was $286.8 million in the full year 2015, compared with $275.7 million in 2014, an increase of 4 percent. International revenue for the full year 2015 was $41.4 million, compared with $45.0 million a year ago. For the year ended December 31, 2015, international revenue was reduced by approximately $3.0 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.
More than 107,030 Oncotype DX(®) test results were delivered for the year ended December 31, 2015, an increase of 12 percent, compared with more than 95,610 test results delivered in 2014. In the fourth quarter of 2015, more than 27,730 Oncotype DX test results were delivered, an increase of 12 percent, compared with more than 24,770 test results delivered in the same period in 2014. Prostate tests delivered in the United States for the full year grew 75 percent compared to the prior year and represented approximately 8 percent of total test volume in 2015. International tests delivered in the full-year grew 19 percent compared to the prior year and represented approximately 21 percent of total test volume in 2015.
"We expect the strong momentum generated across our business in 2015, combined with new compelling global prospective outcomes evidence for the Oncotype DX breast cancer test and recent Medicare coverage for the Oncotype DX prostate cancer test, to lead to double-digit test and revenue growth in 2016," said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. "Additionally, we are excited to continue our impact in making cancer care smarter by launching our first liquid biopsy test, Oncotype SEQ(TM), in mid-2016."
Operating loss for the fourth quarter narrowed to $3.5 million compared with $6.0 million for the fourth quarter of 2014. Net loss was $3.2 million for the fourth quarter of 2015 and includes a $0.8 million tax credit in the quarter resulting from a change in fair value of the company's investment in a marketable security. Basic and diluted net loss per share was $0.10 for the fourth quarter of 2015 compared with basic and diluted net loss per share of $0.20 for the same period in 2014.
Additional Year-End 2015 Financial Results
Operating loss was $34.5 million for the year ended December 31, 2015, compared with an operating loss of $23.6 million for the year ended December 31, 2014. The operating loss for the year ended December 31, 2015 includes a non-recurring first quarter charge of $5.5 million in R&D associated with the wind-down of a breast cancer collaboration.
Net loss was $33.8 million for the year ended December 31, 2015, compared with a net loss of $24.6 million for the year ended December 31, 2014. Basic and diluted net loss per share was $1.04 for the year ended December 31, 2015, compared with a basic and diluted net loss per share of $0.78 for the year ended December 31, 2014.
Cash and cash equivalents and short-term investments at December 31, 2015 were $76.8 million, excluding the fair value of the company's investment in a marketable security of $18.1 million, compared with $103.7 million at December 31, 2014.
2016 Financial Guidance
"In 2016 we plan to deliver double-digit test and revenue growth and improve our net loss, while delivering positive EBITDA(*)," said Brad Cole, Chief Operating Officer and Chief Financial Officer of Genomic Health. "We expect our net loss in the first half of the year to be within the full year loss guidance of $12 to $18 million and to move toward profitability in the second half of the year."
The company is providing the following financial guidance for the full year ending December 31, 2016:
-- Total revenue of $320 to $335 million, representing growth of between 12
and 17 percent compared to 2015;
-- Net loss between $12 and $18 million at the mid-point of revenue
guidance, excluding the effect of the company's investment in a
marketable security, or basic net loss per share of between $0.37 and
$0.55; and
-- Oncotype DX tests delivered of 117,500 to 121,000, representing growth
of between 10 and 13 percent compared to 2015.
(*)EBITDA, or earnings before interest, taxes, depreciation and amortization, is a non-GAAP term.
Recent Business Highlights:
Oncotype DX Commercial Progress
-- Implemented new enterprise-wide platform (ERP) to add novel capabilities
and provide the ability to scale the company's growing business.
-- Expanded coverage of the Oncotype DX breast cancer test for patients
with 1-3 positive nodes to include 11 million additional lives through
new policies with Health Net, Blue Cross Blue Shield of Florida and
Independent Blue Cross. This brings the total number of node-positive
covered lives to more than 161 million U.S. lives.
-- Received positive reimbursement decisions for the Oncotype DX breast
cancer test in four additional regions of Spain bringing the total
number of ex-U.S. lives covered to 196 million.
-- The Centers for Medicare and Medicaid Services (CMS), which administers
the Medicare program, issued its final Clinical Laboratory Fee Schedule
(CLFS) for 2016, which will allow the Medicare Administrative Contractor
(MAC) to continue to set payment for the Oncotype DX colon cancer test
through 2016, as has been done since initiation of coverage in 2011.
Pipeline, Presentations and Publications
-- Announced plans to launch first liquid biopsy test, Oncotype SEQ(TM), a
blood-based mutation panel that uses next-generation sequencing to
identify select actionable genomic alterations for the treatment of
patients with late-stage lung, breast, colon, melanoma, ovarian or
gastrointestinal cancer, in mid-2016. Oncotype SEQ represents the first
of several liquid biopsy tests that Genomic Health plans to deliver
through the introduction of its Oncotype IQ(TM) Genomic Intelligence
Platform.
-- Urology published a meta-analysis of the original Oncotype DX clinical
validation studies demonstrating the ability of the Genomic Prostate
Score (GPS) to refine risk stratification for low- and intermediate-risk
patients with greater precision compared to clinical classifiers alone.
-- Positive results from a large prospective outcomes study in Germany were
accepted for publication in the Journal of Clinical Oncology. Led by the
Women's Healthcare Study Group, the PlanB study demonstrated that women
with breast Recurrence Score(®) results of 11 or less who were treated
with hormonal therapy alone had excellent outcomes with 98 percent
disease-free survival rates at three years despite having intermediate-
or high-risk disease by traditional parameters.
-- Received acceptance to present five year outcomes data from the PlanB
study in an oral presentation at the upcoming European Breast Cancer
Conference in March.
-- Announced results from multiple Oncotype DX breast cancer test studies
at the 38(th) CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
reconfirming that Oncotype DX accurately predicts clinical outcomes -
including risk of recurrence and breast cancer survival - in early-stage
patients with invasive breast cancer. Data include results from the
Surveillance, Epidemiology, and End Results (SEER) program of the
National Cancer Institute (NCI); complete results from a multi-center
study from Clalit Health Services, the largest health maintenance
organization in Israel; additional analyses from the NCI-sponsored Trial
Assigning IndividuaLized Options for Treatment (Rx), or TAILORx; and the
German PlanB study.
Conference Call Details
To access the live conference call today, February 10 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1 (224) 357-2389 internationally. The conference ID is 34365800. Please dial in approximately ten minutes prior to the start of the call. To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at http://investor.genomichealth.com/events.cfm. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ(TM) Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating the company's beliefs regarding its liquid biopsy platform and the timing of a liquid biopsy test; the company's intent to continue its investments in DCIS, prostate cancer and international markets; the company's full year 2015 results; the attributes and focus of the company's product pipeline; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies and their impact on reimbursement and adoption; the applicability of clinical study results to actual outcomes; the company's ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
GENOMIC HEALTH, INC.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
------------ ------------
2015 2014 2015 2014
---- ---- ---- ----
Unaudited Unaudited
REVENUES:
Product revenues - United
States $63,918 $58,794 $245,378 $230,657
Product revenues - Outside
of the United States 10,582 10,332 41,447 45,049
------ ------ ------ ------
Total revenues 74,500 69,126 286,825 275,706
OPERATING EXPENSES (1)(2):
Cost of product revenues 14,078 12,501 53,591 48,742
Research and development 12,605 12,549 59,798 53,076
Selling and marketing 35,593 35,144 143,557 137,846
General and administrative 15,755 14,919 64,348 59,669
------ ------ ------ ------
Total operating expenses 78,031 75,113 321,294 299,333
------ ------ ------- -------
Loss from operations (3,531) (5,987) (34,469) (23,627)
Interest income 58 48 221 192
Other income (expense), net (291) (227) (498) (764)
---- ---- ---- ----
Loss before income taxes (3,764) (6,166) (34,746) (24,199)
------ ------ ------- -------
Income tax expense (benefit) (587) 101 (996) 393
---- --- ---- ---
Net loss $(3,177) $(6,267) $(33,750) $(24,592)
======= ======= ======== ========
Basic and diluted net loss
per share $(0.10) $(0.20) $(1.04) $(0.78)
====== ====== ====== ======
Shares used in computing
basic and diluted net loss
per share 32,645 31,791 32,382 31,453
====== ====== ====== ======
(1) Included in operating expenses for
the three months ended December
31, 2015 were non-cash charges
of $6.0 million, including $4.0
million of stock-based
compensation expense and $2.0
million of depreciation and
amortization expenses, compared
with non-cash charges for the
same period in 2014 of $5.6
million, including $3.9 million
of stock-based compensation
expense and $1.7 million of
depreciation and amortization
expenses.
(2) Included in operating expenses for
the twelve months ended December
31, 2015 were non-cash charges
of $23.1 million, including $16.0
million of stock-based
compensation expense and $7.1
million of depreciation and
amortization expenses, compared
with non-cash charges for the
same period in 2014 of $23.4
million, including $16.5 million
of stock-based compensation
expense and $6.9 million of
depreciation and amortization
expenses.
GENOMIC HEALTH, INC.
Condensed Consolidated Balance Sheets
(In thousands)
As of As of
December 31, December 31,
2015 2014
---- ----
(Unaudited) (1)
Cash and cash equivalents $32,533 $29,726
Short-term marketable
securities (2) 62,410 73,934
Accounts receivable, net 36,531 34,916
Prepaid expenses and other
current assets 10,844 9,944
------ -----
Total current assets 142,318 148,520
Property and equipment, net 39,746 21,860
Other assets 1,921 15,541
----- ------
Total assets $183,985 $185,921
======== ========
Accounts payable $8,395 $6,987
Accrued expenses and other
current liabilities 33,656 31,016
Deferred revenues 431 335
Other liabilities 2,410 2,070
Stockholders' equity 139,093 145,513
------- -------
Total liabilities and
stockholders' equity $183,985 $185,921
======== ========
(1) The condensed consolidated
balance sheet at December 31,
2014, has been derived from the
audited consolidated financial
statements at that date
included in the Company's
Annual Report on Form 10-K for
the fiscal year ended December
31, 2014.
(2) Included in short-term
marketable securities as of
December 31, 2015, was $18.1
million of corporate equity
securities, representing the
Company's investment in Invitae
Corporation.
http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO
Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomic-health-announces-2016-financial-outlook-and-provides-2015-fourth-quarter-and-year-end-financial-results-300218391.html
SOURCE Genomic Health, Inc.
